copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
About Us | A global leader in genomics - Illumina Illumina Solutions Centers around the world are places of learning, community, and training for our customers and partners to impact outcomes for human health in every region Fully operational labs with bespoke training opportunities mean we enable every corner of the globe to learn, optimize, and scale their genomics capabilities and expertise
Illumina, Other Genomics Fims Ramp Up Data Offerings for Pharma, With . . . Illumina has already partnered with Broad Clinical Labs to create a 5 billion cell Perturb-seq atlas using Illumina's single-cell technology BioInsight will also encompass other aspects of Illumina's business, with a group of more than 500 people led by Illumina veteran Rami Mehio
Illumina (NASDAQ:ILMN) Upgraded at Zacks Research - MarketBeat Key Points Zacks Research upgraded Illumina from a "hold" to a strong-buy in a Tuesday report, though MarketBeat's consensus across analysts remains a "Hold" with an average price target of $115 Illumina beat the quarter with EPS of $1 34 (vs $1 16 expected) and $1 08B in revenue, and issued FY2025 guidance of 4 650–4 750 EPS Shares opened at $127 95 and trade in a 52‑week range of $68
Statement Regarding Illumina’s Decision to Divest Grail Illumina, Inc announced it would divest Grail, Inc following a U S Court of Appeals for the Fifth Circuit decision that supported the Federal Trade Commission’s determination that the acquisition threatened competition in the market for cancer detection tests Federal Trade Commission Bureau of Competition Director Henry Liu issued the following statement: “This is a major win for the
Genomics products | Illumina Illumina offers a broad range of sequencing and microarray products for diverse genomic analysis applications